[Receptor (ER, PgR) levels as prognostic factors in the endocrine therapy of pre- and post-menopausal patients with stage III infiltrative ductal and lobular cancer of the breast].
Receptors group (ER+, PgR+) in post-menopausal and pre-menopausal patients with ductal and lobular infiltrating mammary cancer clinical stage III and poorly differentiated histological assessment was studied. Levels of (ER+, PgR+) were correlated to endocrine therapy response (Tamoxifen) after 5 years of its administration. Both pre and post-menopausal patients with infiltrating ductal carcinoma, the (RE+, RPg+) tumour content, the mean values were 52 +/- 8, 53 +/- 11 fmol/mg protein and 111 +/- 20, 36 +/- 7 fmol/mg protein, respectively. With regard to lobular carcinoma, the (RE+, RPg+) tumour content, the mean value was 109 +/- 28, 46 +/- 12 fmol/mg protein in pre-menopausal patients, whereas it was 287 +/- 60, 66 +/- 18 fmol/mg protein in post-menopausal patients. The tumour was considered (ER+, PgR+) when specific binding was than 10 fmol/mg protein. In both ductal and lobular carcinoma the mean (ER+) concentrations are significantly different between the post and pre-menopausal patients, while the mean (PgR+) concentrations are significantly different in post-menopausal women. After five years of treatment with tamoxifen, survival analysis of patients with ductal infiltrating and lobular infiltrating carcinoma revealed a very strong correlation between levels of receptor group (ER+, PgR+) and their response to endocrine therapy.
Calzada
L
L
Hospital de Gineco-Obstetricia No. 4 Luis Castelazo Ayala, IMSS México.
Salazar
E L
EL
Pedron Nuevo
N
N
D000328:Adult; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000737:chemistry / Q000188:drug therapy / Q000473:pathology*; D018270:Carcinoma, Ductal, Breast / Q000737:chemistry / Q000188:drug therapy / Q000473:pathology*; D018275:Carcinoma, Lobular / Q000737:chemistry / Q000188:drug therapy / Q000473:pathology*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D017698:Postmenopause; D017697:Premenopause; D011960:Receptors, Estrogen / Q000032:analysis*; D011980:Receptors, Progesterone / Q000032:analysis*; D013629:Tamoxifen / Q000627:therapeutic use*
D018931:Antineoplastic Agents, Hormonal; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D013629:Tamoxifen
Niveles del grupo de receptores (RE, RPg) como factor pronóstico de la terapia endócrina en pacientes pre y posmenopáusicas con carcinoma mamario ductal y lobulillar infiltrante en etapa clínica III.